Dr James Khodabakhsh MD speaks to Proactive's Andrew Scott following his appointment as chair of OKYO Pharma Limited's (LON:OKYO) Scientific Advisory Board. He'll be tasked with bringing together a small group of leaders to review and inform the company's plans to progress its lead product candidate Chemerin to an IND in the indication of dry-eye disease.
OKYO Pharma Limited appoints top Beverly Hills surgeon to lead its Scientific Advisory Board
Quick facts: Okyo Pharma Limited
Price: 10.18 GBX
Market Cap: £68.47 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Okyo Pharma Limited named herein, including the promotion by the Company of Okyo Pharma Limited in any Content on the Site, the Company...FOR OUR FULL DISCLAIMER CLICK HERE